Hercules Congratulates Portfolio Company Edge Therapeutics on its Initial Public Offering
October 02 2015 - 5:00AM
Business Wire
- Twelve (12) Hercules Portfolio
Companies Completed or Announced IPO and M&A Liquidity Events
Year-to-Date 2015
- Hercules Currently Has Six (6)
Portfolio Companies in IPO Registration
- Hercules Holds Warrant Positions in 131
Pre-IPO or M&A Portfolio Companies, as of June 30, 2015,
Representing Potential Future Additional Returns to Investors*
- Hercules Holds Equity Positions in 47
Pre-IPO or M&A Portfolio Companies, as of June 30, 2015,
Representing Potential Future Additional Returns to Investors*
Hercules Technology Growth Capital, Inc. (NYSE:HTGC) (“Hercules”
or the “Company”), the leading specialty finance company to
innovative, high-growth venture capital-backed companies, today
noted that its portfolio company, Edge Therapeutics, Inc.,
completed its initial public offering (“IPO”) on October 1, 2015.
Edge Therapeutics, a clinical-stage biotechnology company
developing therapies capable of transforming treatment paradigms in
the management of acute, life-threatening neurological conditions,
included approximately 7.3 million shares of its common stock at
$11.00 per share in the offering, raising approximately $80
million. Shares of the company are trading on the NASDAQ Global
Market under the symbol “EDGE.”
Hercules initially committed $10 million in venture debt
financing to Edge Therapeutics in August 2014.
As of October 1, 2015, Hercules currently has six (6)
additional portfolio companies who have either publicly or
confidentially filed Form S-1 Registration Statements with the SEC
in contemplation of a potential IPO. However, there can be no
assurances that these companies will complete their IPOs in a
timely manner or at all.
- Gelesis, Inc.
- Cerecor Inc.
- Four (4) companies filed confidentially
under the JOBS Act
*Not all companies will go public or complete an M&A
event.
About Hercules Technology Growth Capital, Inc.
Hercules Technology Growth Capital, Inc. (NYSE:HTGC)
(“Hercules”) is the leading specialty finance company focused on
providing senior secured venture growth loans to high-growth,
innovative venture capital-backed companies in the technology,
biotechnology, life sciences, healthcare, and energy &
renewable technology industries. Since inception (December 2003),
Hercules has committed more than $5.5 billion to over 325 companies
and is the lender of choice for entrepreneurs and venture capital
firms seeking growth capital financing. Companies interested in
learning more about financing opportunities should contact
info@htgc.com, or call 650.289.3060.
Hercules’ common stock trades on the New York Stock Exchange
(NYSE) under the ticker symbol "HTGC."
In addition, Hercules has three outstanding bond issuances of
7.00% Notes due April 2019, 7.00% Notes due September 2019, and
6.25% Notes due July 2024, which trade on the NYSE under the
symbols “HTGZ,” “HTGY,” and “HTGX,” respectively.
Forward-Looking Statements:
The information disclosed in this release is made as of the date
hereof and reflects Hercules most current assessment of its
historical financial performance. Actual financial results filed
with the Securities and Exchange Commission may differ from those
contained herein due to timing delays between the date of this
release and confirmation of final audit results. These
forward-looking statements are not guarantees of future performance
and are subject to uncertainties and other factors that could cause
actual results to differ materially from those expressed in the
forward-looking statements including, without limitation, the
risks, uncertainties, including the uncertainties surrounding the
current market volatility, and other factors we identify from time
to time in our filings with the Securities and Exchange Commission.
Although we believe that the assumptions on which these
forward-looking statements are based are reasonable, any of those
assumptions could prove to be inaccurate and, as a result, the
forward-looking statements based on those assumptions also could be
incorrect. You should not place undue reliance on these
forward-looking statements. The forward-looking statements
contained in this release are made as of the date hereof, and
Hercules assumes no obligation to update the forward-looking
statements for subsequent events.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151002005128/en/
Hercules Technology Growth Capital, Inc.Michael Hara,
650-433-5578 HT-HNInvestor Relations and Corporate
Communicationsmhara@htgc.com
Hercules Capital (NYSE:HTGC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hercules Capital (NYSE:HTGC)
Historical Stock Chart
From Jul 2023 to Jul 2024